Nature Communications (Dec 2022)

Engineered Lactococcus lactis secreting Flt3L and OX40 ligand for in situ vaccination-based cancer immunotherapy

  • Junmeng Zhu,
  • Yaohua Ke,
  • Qin Liu,
  • Ju Yang,
  • Fangcen Liu,
  • Ruihan Xu,
  • Hang Zhou,
  • Aoxing Chen,
  • Jie Xiao,
  • Fanyan Meng,
  • Lixia Yu,
  • Rutian Li,
  • Jia Wei,
  • Baorui Liu

DOI
https://doi.org/10.1038/s41467-022-35130-7
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 18

Abstract

Read online

The probiotic Lactococcus lactis has been used for the delivery of therapeutic molecules. Here the authors engineer Lactococcus lactis to express a fusion protein of Flt3L and OX40 ligand, eliciting anti-tumor immune response in preclinical cancer models.